Riskpilot← Back to searchSign inGet full accessONCOMAL ApS
APSActiveCVR 34580367Nordre Fasanvej 215Activities of holding companies · NACE 6421Est. 2012— employees
Revenue 2024
DKK -171K
+216% vs 2023
EBITDA margin
100.0%
-216% vs 2023
Equity ratio
83.5%
Financial strength
Net profit 2024
DKK -1,2M
-68% vs 2023
| Revenue | DKK -171K | +216% |
| EBITDA | DKK -171K | -216% |
| Net profit | DKK -1,2M | -68% |
| Total assets | DKK 164,1M | +35% |
| Equity | DKK 137M | +36% |
| Employees | — | — |
Legal name
ONCOMAL ApS
CVR number
34580367
Legal form
Anpartsselskab
NACE code
6421 · Activities of holding companies
Founded
9. maj 2012
Share capital
DKK 132.875
Employees
—
VAT registered
No
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsens formand i forening med et bestyrelsesmedlem eller en direktør eller af den samlede bestyrelse.
Company purpose
Selskabets formål er - direkte eller via besiddelse af kapitalandele i andre selskaber at drive virksomhed indenfor kræftbekæmpelse samt anden virksomhed, der efter bestyrelsens skøn er forbundet dermed.
Address
Nordre Fasanvej 215
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -7 | -84 | -16 | -12 | -252 | -66 | -344 | -35 | -39 | -321 | -230 | -54 | -171 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -7 | -84 | -16 | -12 | -252 | -66 | -344 | -35 | -39 | -321 | -230 | -54 | -171 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -7 | -84 | -16 | -12 | -252 | -66 | -344 | -35 | -39 | -321 | -230 | -54 | -171 |
| Net financials | 0 | -1 | 12 | 20 | -17 | -39 | -101 | -166 | -268 | -377 | -512 | -840 | -1.321 |
| Profit before tax | -7 | -84 | -4 | 8 | -269 | -105 | -445 | -201 | -306 | -698 | -742 | -894 | -1.492 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -91 | -69 | -103 | -169 | -276 |
| Net profit | -7 | -84 | -4 | 8 | -269 | -105 | -445 | -201 | -216 | -628 | -639 | -725 | -1.216 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 80 | 80 | 1.919 | 5.395 | 14.089 | 23.760 | 70.218 | 72.238 | 74.187 | 75.894 | 115.686 | 121.221 | 164.053 |
| Equity | 73 | -12 | 1.787 | 5.191 | 13.105 | 21.184 | 66.187 | 65.986 | 65.770 | 65.142 | 101.700 | 100.974 | 137.043 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 8 | 92 | 132 | 203 | 984 | 2.575 | 4.031 | 6.252 | 8.416 | 10.752 | 13.987 | 20.247 | 27.010 |
| Total debt | 8 | 92 | 132 | 203 | 984 | 2.575 | 4.031 | 6.252 | 8.416 | 10.752 | 13.987 | 20.247 | 27.010 |
EBITDA margin
-17149300.0%
This company
15.8%
Market median
-108539973% vs market
20122024
Equity ratio
83.5%
This company
38.2%
Market median
+119% vs market
20122024
Return on equity
-0.9%
This company
18.4%
Market median
-105% vs market
20122024
Net profit margin
-121624300.0%
This company
8.1%
Market median
-1501534668% vs market
20122024
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20122024
Debt / equity
0.20×
This company
0.62×
Market median
+68% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-05-09 – 2012-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2016 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 20.0% | 20.0% | 2024 | |
| Individual | 20.0% | 20.0% | 2025 | |
| Individual | 10.0% | 10.0% | 2018 | |
| Individual | 10.0% | 10.0% | 2024 | |
| Individual | 5.0% | 5.0% | 2025 | |
| Individual | 5.0% | 5.0% | 2012 | |
| Individual | 5.0% | 5.0% | 2012 | |
| Individual | 5.0% | 5.0% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ONCOMAL ApS 
VAR2 PHARMACEUTICALS ApSBoard members of ONCOMAL ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Peter Schröcksnadel | Board of Directors | 0 companies |
| Josef Rainer | Board of Directors | 0 companies |
| Silviya Stoykova | Board of Directors | 0 companies |
| Mai-Britt Zocca | Board of Directors | 0 companies |
| Tanja Rainer | Board of Directors | 0 companies |
| Poul Henrik Bredahl Sørensen | Board of Directors | 0 companies |